Stryker Co. (NYSE:SYK) Shares Sold by Private Wealth Partners LLC

Private Wealth Partners LLC lowered its position in Stryker Co. (NYSE:SYK) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 32,063 shares of the medical technology company’s stock after selling 677 shares during the period. Private Wealth Partners LLC’s holdings in Stryker were worth $11,544,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Dunhill Financial LLC raised its holdings in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the period. Darwin Wealth Management LLC purchased a new stake in shares of Stryker in the third quarter valued at approximately $36,000. Activest Wealth Management acquired a new position in shares of Stryker during the 4th quarter worth approximately $36,000. Crews Bank & Trust purchased a new position in shares of Stryker during the 4th quarter valued at approximately $39,000. Finally, Hara Capital LLC acquired a new stake in Stryker in the 3rd quarter valued at $42,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Price Performance

Shares of SYK stock opened at $388.30 on Thursday. The firm’s 50-day moving average is $377.69 and its two-hundred day moving average is $368.08. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market capitalization of $148.17 billion, a PE ratio of 50.04, a price-to-earnings-growth ratio of 2.90 and a beta of 0.96.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm posted $3.46 EPS. Analysts predict that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SYK. Wells Fargo & Company upped their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. UBS Group raised their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and set a $442.00 price objective on shares of Stryker in a research note on Wednesday, January 29th. Truist Financial raised their target price on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. Finally, BTIG Research boosted their price target on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $420.68.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.